Validation of SCT methylation as a hallmark biomarker for lung cancers

Journal of Thoracic Oncology

Volumn 11, Issue 3, 2016, Pages 346-360

  Zhang, Yu An ^a,b   Ma, Xiaotu ^c,d   Sathe, Adwait ^c   Fujimoto, Junya ^e   Wistuba, Ignacio I ^e   Lam, Stephen ^f   Yatabe, Yasushi ^g   Wang, Yi Wei ^a   Stastny, Victor ^a   Gao, Boning ^a   Larsen, Jill E ^a   Girard, Luc ^a   Liu, Xiaoyun ^a   Song, Kai ^a,h   Behrens, Carmen ^e   Kalhor, Neda ^e   Xie, Yang ^a   Zhang, Michael Q ^c,i   Minna, John D ^a,b,j   Gazdar, Adi F ^a,b,j  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS AT DALLAS   (United States)

^d ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^e UNIVERSITY OF TEXAS   (United States)

^f BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^g AICHI CANCER CENTER HOSPITAL   (Japan)

^h TIANJIN UNIVERSITY   (China)

ⁱ TSINGHUA UNIVERSITY   (China)

^j UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

more..

Author keywords

Cancer biomarker; FFPE DNA SCT qMSP; Lung cancer; SCT methylation; Secretin

Indexed keywords

BIOLOGICAL MARKER; BISULFITE; SECRETIN; TUMOR MARKER;

ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG CARCINOGENESIS; METHYLATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SQUAMOUS CELL CARCINOMA; VALIDATION STUDY; CPG ISLAND; DNA METHYLATION; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; NON SMALL CELL LUNG CANCER; PROMOTER REGION; TUMOR CELL LINE;

BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CPG ISLANDS; DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; PROMOTER REGIONS, GENETIC; SECRETIN; SEQUENCE ANALYSIS, DNA;

EID: 84962621516     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2015.11.004     Document Type: Article

References (59)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011; 61: 69-90.
2. Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin. 2014; 64: 9-29.
3. Esteller M. Epigenetics in cancer. N Engl J Med. 2008; 358: 1148-1159.
4. Ma X, Wang YW, Zhang MQ, et al. DNA methylation data analysis and its application to cancer research. Epigenomics. 2013; 5: 301-316.
5. Selamat SA, Chung BS, Girard L, et al. Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with mRNA expression. Genome Res. 2012; 22: 1197-1211.
6. Tessema M, Belinsky SA. Mining the epigenome for methylated genes in lung cancer. Proc Am Thorac Soc. 2008; 5: 806-810.
7. Selamat SA, Galler JS, Joshi AD, et al. DNA methylation changes in atypical adenomatous hyperplasia, adenocarcinoma in situ, and lung adenocarcinoma. PLoS One. 2011; 6: e21443.
8. Sandoval J, Heyn H, Mendez-Gonzalez J, et al. Genomewide DNA methylation profiling predicts relapse in childhood B-cell acute lymphoblastic leukaemia. Br J Haematol. 2013; 160: 406-409.
9. Sandoval J, Mendez-Gonzalez J, Nadal E, et al. A prognostic DNA methylation signature for stage I nonsmall-cell lung cancer. J Clin Oncol. 2013; 31: 4140-4147.
10. Liloglou T, Bediaga NG, Brown BR, et al. Epigenetic biomarkers in lung cancer. Cancer Lett. 2014; 342: 200-212.
11. Tsou JA, Shen LY, Siegmund KD, et al. Distinct DNA methylation profiles in malignant mesothelioma, lung adenocarcinoma, and non-Tumor lung. Lung Cancer. 2005; 47: 193-204.
12. Tsou JA, Galler JS, Siegmund KD, et al. Identification of a panel of sensitive and specific DNA methylation markers for lung adenocarcinoma. Mol Cancer. 2007; 6: 70.
13. Shivapurkar N, Stastny V, Suzuki M, et al. Application of a methylation gene panel by quantitative PCR for lung cancers. Cancer Lett. 2007; 247: 56-71.
14. Brock MV, Hooker CM, Ota-Machida E, et al. DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med. 2008; 358: 1118-1128.
15. Nikolaidis G, Raji OY, Markopoulou S, et al. DNA methylation biomarkers offer improved diagnostic efficiency in lung cancer. Cancer Res. 2012; 72: 5692-5701.
16. Schmidt B, Liebenberg V, Dietrich D, et al. SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer based on bronchial aspirates. BMC Cancer. 2010; 10: 600.
17. Schneider KU, Dietrich D, Fleischhacker M, et al. Correlation of SHOX2 gene amplification and DNA methylation in lung cancer tumors. BMC Cancer. 2011; 11: 102.
18. Bayliss WM, Starling EH. The mechanism of pancreatic secretion. J Physiol. 1902; 28: 325-353.
19. Sekar R, Chow BK. Metabolic effects of secretin. Gen Comp Endocrinol. 2013; 181: 18-24.
20. Chey WY, Escoffery R. Secretion cells in the gastrointestinal tract. Endocrinology. 1976; 98: 1390-1395.
21. Yamagata T, Aradhya S, Mori M, et al. The human secretin gene: fine structure in 11p15.5 and sequence variation in patients with autism. Genomics. 2002; 80: 185-194.
22. Lam IP, Siu FK, Chu JY, et al. Multiple actions of secretin in the human body. Int Rev Cytol. 2008; 265: 159-190.
23. Whitmore TE, Holloway JL, Lofton-Day CE, et al. Human secretin (SCT): gene structure, chromosome location, and distribution of mRNA. Cytogenet Cell Genet. 2000; 90: 47-52.
24. Lee LT, Tan-Un KC, Pang RT, et al. Regulation of the human secretin gene is controlled by the combined effects of CpG methylation, Sp1/Sp3 ratio, and the E-box element. Mol Endocrinol. 2004; 18: 1740-1755.
25. Onori P, Wise C, Gaudio E, et al. Secretin inhibits cholangiocarcinoma growth via dysregulation of the cAMPdependent signaling mechanisms of secretin receptor. Int J Cancer. 2010; 127: 43-54.
26. The Cancer Genome Atlas. TCGA portal overview. https: //tcga-data.nci.nih.gov/tcga/. Accessed April 1, 2015.
27. Cancer Genome Atlas Research N. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014; 511: 543-550.
28. Carter SL, Cibulskis K, Helman E, et al. Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol. 2012; 30: 413-421.
29. Yoshihara K, Shahmoradgoli M, Martinez E, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013; 4: 2612.
30. Akbani R, Ng PK, Werner HM, et al. A pan-cancer proteomic perspective on The Cancer Genome Atlas. Nat Commun. 2014; 5: 3887.
31. Hawes SE, Stern JE, Feng Q, et al. DNA hypermethylation of tumors from non-small cell lung cancer (NSCLC) patients is associated with gender and histologic type. Lung Cancer. 2010; 69: 172-179.
32. Sato M, Larsen JE, Lee W, et al. Human lung epithelial cells progressed to malignancy through specific oncogenic manipulations. Mol Cancer Res. 2013; 11: 638-650.
33. Shi SR, Datar R, Liu C, et al. DNA extraction from archival formalin-fixed, paraffin-embedded tissues: heat-induced retrieval in alkaline solution. Histochem Cell Biol. 2004; 122: 211-218.
34. Taga M, Eguchi H, Shinohara T, et al. Improved PCR amplification for molecular analysis using DNA from longterm preserved formalin-fixed, paraffin-embedded lung cancer tissue specimens. Int J Clin Exp Pathol. 2013; 6: 76-79.
35. Han W, Cauchi S, Herman JG, et al. DNA methylation mapping by tag-modified bisulfite genomic sequencing. Anal Biochem. 2006; 355: 50-61.
36. Grote HJ, Schmiemann V, Kiel S, et al. Aberrant methylation of the adenomatous polyposis coli promoter 1A in bronchial aspirates from patients with suspected lung cancer. Int J Cancer. 2004; 110: 751-755.
37. Walter K, Holcomb T, Januario T, et al. DNA methylation profiling defines clinically relevant biological subsets of non-small cell lung cancer. Clin Cancer Res. 2012; 18: 2360-2373.
38. Coin: conditional inference procedures in a permutation test framework. http: //cran.r-project.org/web/packages/coin/index.html. Accessed September 9, 2014.
39. Cancer Genome Atlas Research N. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012; 489: 519-525.
40. Rosenbloom KR, Sloan CA, Malladi VS, et al. ENCODE data in the UCSC Genome Browser: year 5 update. Nucleic Acids Res. 2013; 41: D56-D63.
41. Sathe A, Zhang Y-A, Ma X, et al. SCT promoter methylation is a highly discriminative biomarker for lung and many other cancers. IEEE Life Sciences Letters. 2015; 1: 30-33.
42. Tournier B, Chapusot C, Courcet E, et al. Why do results conflict regarding the prognostic value of the methylation status in colon cancers? The role of the preservation method. BMC Cancer. 2012; 12: 12.
43. Bonin S, Petrera F, Niccolini B, et al. PCR analysis in archival postmortem tissues. Mol Pathol. 2003; 56: 184-186.
44. Dedhia P, Tarale S, Dhongde G, et al. Evaluation of DNA extraction methods and real time PCR optimization on formalin-fixed paraffin-embedded tissues. Asian Pac J Cancer Prev. 2007; 8: 55-59.
45. Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. J Thorac Oncol. 2011; 6: 244-285.
46. Wistuba II , Gazdar AF. Lung cancer preneoplasia. Annual review of pathology. 2006; 1: 331-348.
47. Ramirez RD, Sheridan S, Girard L, et al. Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer Res. 2004; 64: 9027-9034.
48. Vikis H, Sato M, James M, et al. EGFR-T790M is a rare lung cancer susceptibility allele with enhanced kinase activity. Cancer Res. 2007; 67: 4665-4670.
49. Lange CP, Campan M, Hinoue T, et al. Genome-scale discovery of DNA-methylation biomarkers for bloodbased detection of colorectal cancer. PLoS One. 2012; 7: e50266.
50. Kadara H, Fujimoto J, Yoo SY, et al. Transcriptomic architecture of the adjacent airway field cancerization in non-small cell lung cancer. J Natl Cancer Inst. 2014; 106: dju004.
51. Toyooka S, Toyooka KO, Maruyama R, et al. DNA methylation profiles of lung tumors. Mol Cancer Ther. 2001; 1: 61-67.
52. American Cancer Society. Thyroid cancer survival by type and stage. http: //www.cancer.org/cancer/thyroidcancer/detailedguide/thyroid-cancer-survivalrates. Accessed July 30, 2015.
53. Strobel P, Bauer A, Puppe B, et al. Tumor recurrence and survival in patients treated for thymomas and thymic squamous cell carcinomas: A retrospective analysis. J Clin Oncol. 2004; 22: 1501-1509.
54. Edmonds S, Fein DM, Gurtman A. Pheochromocytoma. Pediatr Rev. 2011; 32: 308-310.
55. Nazor KL, Altun G, Lynch C, et al. Recurrent variations in DNA methylation in human pluripotent stem cells and their differentiated derivatives. Cell Stem Cell. 2012; 10: 620-634.
56. Novakovic B, Saffery R. Placental pseudo-malignancy from a DNA methylation perspective: unanswered questions and future directions. Front Genet. 2013; 4: 285.
57. Novakovic B, Saffery R. DNA methylation profiling highlights the unique nature of the human placental epigenome. Epigenomics. 2010; 2: 627-638.
58. Schroeder DI, Blair JD, Lott P, et al. The human placenta methylome. Proc Natl Acad Sci U S A. 2013; 110: 6037-6042.
59. The Human Protein Atlas. SCT. http: //www.proteinatlas. org/ENSG00000070031-SCT/tissue. Accessed October 20, 2015.